AXSOME THERAPEUTICS, INC.

(AXSM)
  Report
Delayed Nasdaq  -  04:00 2022-08-12 pm EDT
46.27 USD   +2.10%
08/10Morgan Stanley Raises Axsome Therapeutics Price Target to $55 From $54, Maintains Equalweight Rating
MT
08/10Cantor Fitzgerald Adjusts Price Target on Axsome Therapeutics to $54 From $64, Reiterates Overweight Rating
MT
08/09AXSOME THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Axsome Therapeutics, Inc. Receives from the U.S. Food and Drug Administration

06/27/2022 | 07:05am EDT

On June 24, 2022, Axsome Therapeutics, Inc. received from the U.S. Food and Drug Administration (the “FDA”) proposed labeling for the Company's AXS-05 product candidate with respect to its New Drug Application (the “NDA”) for AXS-05 for the treatment of major depressive disorder. The Company is reviewing the proposed labeling and will reply to the FDA to secure final labeling agreement.


© S&P Capital IQ 2022
All news about AXSOME THERAPEUTICS, INC.
08/10Morgan Stanley Raises Axsome Therapeutics Price Target to $55 From $54, Maintains Equal..
MT
08/10Cantor Fitzgerald Adjusts Price Target on Axsome Therapeutics to $54 From $64, Reiterat..
MT
08/09AXSOME THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ..
AQ
08/09Axsome Therapeutics Reports Wider Loss in Q2; Shares Drop Pre-Bell
MT
08/09TRANSCRIPT : Axsome Therapeutics, Inc., Q2 2022 Earnings Call, Aug 09, 2022
CI
08/09AXSOME : Q2 Earnings Snapshot
AQ
08/09Axsome Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Month..
CI
08/09Axsome Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business..
GL
08/09Axsome Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business..
AQ
08/09NORTH AMERICAN MORNING BRIEFING : Stocks to -2-
DJ
More news
Analyst Recommendations on AXSOME THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 54,2 M - -
Net income 2022 -172 M - -
Net cash 2022 63,2 M - -
P/E ratio 2022 -10,6x
Yield 2022 -
Capitalization 1 865 M 1 865 M -
EV / Sales 2022 33,3x
EV / Sales 2023 8,13x
Nbr of Employees 198
Free-Float 80,1%
Chart AXSOME THERAPEUTICS, INC.
Duration : Period :
Axsome Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AXSOME THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 46,27 $
Average target price 85,91 $
Spread / Average Target 85,7%
EPS Revisions
Managers and Directors
Herriott Tabuteau Chairman & Chief Executive Officer
Nick Pizzie Chief Financial & Accounting Officer
Joseph Debrah-Afful Controller
Amanda Jones Senior Vice President-Clinical Development
Mark L. Jacobson Secretary & Senior Director-Operations
Sector and Competitors
1st jan.Capi. (M$)
AXSOME THERAPEUTICS, INC.22.47%1 865
GILEAD SCIENCES, INC.-13.29%78 912
VERTEX PHARMACEUTICALS34.12%75 532
REGENERON PHARMACEUTICALS, INC.-0.45%67 214
WUXI APPTEC CO., LTD.-20.10%40 830
BIONTECH SE-37.80%38 968